Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
In a “generalized HIV epidemic,” what if all transmission during sex work stopped? Call it a different kind of 1 percent — the kind that doesn’t […]
The TB Alliance Wednesday announced the launch of the first clinical trial testing an all-oral regimen to treat extensively- drug resistant tuberculosis. With a three drug […]
Study highlights need to test patients for antiretroviral resistance in resource-limited settings as well as in wealthy ones
Study also finds HIV subtype most common in Africa progresses the fastest A multinational study has spelled out two ways the cards are stacked against those […]
Meanwhile, crisis continues, while future readiness remains an open question Ebola had already hit the big time, making its first appearance in a capital city nearly […]